
  
    
      
        Introduction_NNP
        Breast_NNP cancer_NN is_VBZ predicted_VBN to_TO be_VB newly_RB diagnosed_VBN in_IN
        about_IN 211_CD ,_, 300_CD women_NNS in_IN 2003_CD in_IN the_DT United_NNP States_NNPS [_NN 1_CD 2_CD ]_NN ._.
        Twelve_CD percent_NN of_IN all_DT women_NNS will_MD be_VB diagnosed_VBN with_IN breast_NN
        cancer_NN in_IN their_PRP$ lifetime_NN ,_, and_CC 3_CD ._. 5_CD %_NN will_MD die_NN of_IN the_DT disease_NN ._.
        The_DT cell_NN transformation_NN associated_VBN with_IN breast_NN cancer_NN
        requires_VBZ the_DT coordinated_VBN activation_NN or_CC inhibition_NN of_IN
        specific_JJ intact_JJ or_CC altered_VBN genes_NNS ._. Transcription_NNP factors_NNS
        frequently_RB regulate_VB these_DT processes_NNS ._. An_DT important_JJ type_NN of_IN
        transcription_NN factor_NN contains_VBZ a_DT conserved_JJ region_NN of_IN 60_CD
        amino_JJ acids_NNS called_VBD the_DT homeodomain_NN (_( HD_NNP )_) ,_, encoded_JJ by_IN a_DT DNA_NNP
        region_NN ,_, the_DT homeobox_NN (_( HB_NNP )_) ._. HD_NNP proteins_NNS are_VBP involved_VBN in_IN the_DT
        control_NN of_IN development_NN and_CC differentiation_NN in_IN many_JJ
        organisms_NNS [_NN 3_CD 4_CD ]_NN ._. Initially_RB discovered_VBN in_IN 
        Drosophila_NNP ,_, mutations_NNS of_IN the_DT HB_NNP in_IN
        homeobox_NN genes_NNS result_VBP in_IN vast_JJ morphologic_JJ abnormalities_NNS [_NN 3_CD
        ]_NN ._. Subsequently_NNP ,_, homologous_RB HB_NNP genes_NNS have_VBP been_VBN cloned_VBN in_IN
        many_JJ species_NNS including_VBG humans_NNS [_NN 5_CD 6_CD 7_CD ]_NN ._.
        Vertebrate_NNP HB_NNP genes_NNS are_VBP divided_VBN into_IN two_CD classes_NNS :_: Class_NNP
        I_PRP genes_NNS (_( HOX_NNP genes_NNS )_) are_VBP organized_VBN into_IN four_CD clusters_NNS (_( HOX_NNP
        A_DT ,_, B_NNP ,_, C_NNP ,_, D_NNP )_) with_IN a_DT total_NN of_IN 39_CD members_NNS [_NN 8_CD ]_NN ._. Members_NNS of_IN
        Class_NNP II_NNP are_VBP also_RB called_VBN divergent_JJ genes_NNS ,_, including_VBG genes_NNS
        such_JJ as_IN PAX_NNP ,_, MSX_NNP ,_, IRX_NNP ,_, and_CC DLX_NNP ,_, named_VBN after_IN their_PRP$ homologs_NNS
        in_IN 
        Drosophila_NNP (_( paired_VBN ,_, muscle_NN segment_NN ,_,
        Iroquois_NNP ,_, and_CC distal-less_JJ ,_, respectively_RB )_) [_NN 9_CD 10_CD ]_NN ._.
        Accumulating_NNP evidence_NN suggests_VBZ that_IN homeobox_NN genes_NNS are_VBP
        important_JJ in_IN malignant_JJ transformation_NN ._. Not_RB only_RB have_VBP
        altered_VBN expression_NN levels_NNS of_IN HB_NNP genes_NNS been_VBN detected_VBN in_IN a_DT
        variety_NN of_IN human_JJ malignancies_NNS [_NN 8_CD 11_CD 12_CD 13_CD 14_CD ]_NN ,_, but_CC the_DT
        ectopic_JJ expression_NN of_IN certain_JJ HOX_NNP genes_NNS can_MD induce_VB tumors_NNS [_NN
        15_CD 16_CD 17_CD ]_NN ._. Abnormal_NNP HOX_NNP gene_NN expression_NN has_VBZ been_VBN
        associated_VBN with_IN breast_NN cancer_NN ._. For_IN example_NN ,_, the_DT murine_NN
        Hoxa-_NNP 1_CD gene_NN is_VBZ upregulated_JJ in_IN neoplastic_JJ murine_NN mammary_JJ
        glands_NNS [_NN 18_CD ]_NN ._. In_IN humans_NNS ,_, the_DT lack_NN of_IN HOXA_NNP 5_CD expression_NN
        results_NNS in_IN the_DT loss_NN of_IN p_NN 53_CD expression_NN in_IN breast_NN cancer_NN [_NN 19_CD
        ]_NN ._. Enforced_NNP HOXB_NNP 7_CD expression_NN in_IN SkBr_NNP 3_CD breast_NN cancer_NN cells_NNS
        induces_VBZ the_DT expression_NN of_IN basic_JJ fibroblast_NN growth_NN factor_NN
        and_CC increases_NNS growth_NN rate_NN ,_, serum-independent_JJ growth_NN ,_, and_CC
        the_DT ability_NN of_IN cells_NNS to_TO form_VB colonies_NNS in_IN semisolid_NN medium_NN [_NN
        20_CD ]_NN ._. Nude_NNP mice_NNS ,_, when_WRB injected_VBN with_IN SkBr_NNP 3_CD /_NN HOXB_NNP 7_CD cells_NNS ,_,
        developed_VBN tumors_NNS [_NN 21_CD ]_NN ._.
        We_PRP have_VBP cloned_VBN a_DT human_JJ homeobox_NN cDNA_NN called_VBD BP_NNP 1_CD ,_,
        belonging_VBG to_TO the_DT DLX_NNP family_NN ._. BP_NNP 1_CD is_VBZ apparently_RB involved_VBN in_IN
        the_DT regulation_NN of_IN diverse_JJ pathways_NNS ._. In_IN normal_JJ erythroid_NN
        cells_NNS it_PRP acts_VBZ as_IN a_DT repressor_NN of_IN the_DT β-globin_JJ gene_NN [_NN 22_CD 23_CD ]_NN
        ._. However_RB ,_, BP_NNP 1_CD was_VBD also_RB expressed_VBN in_IN 47_CD %_NN of_IN the_DT adult_NN and_CC
        81_CD %_NN of_IN the_DT pediatric_JJ acute_JJ myeloid_NN leukemia_NN patients_NNS we_PRP
        examined_VBD ,_, and_CC its_PRP$ overexpression_NN increased_VBD the_DT leukemogenic_JJ
        potential_NN of_IN K_NNP 562_CD cells_NNS 
        in_IN vitro_NN [_NN 11_CD ]_NN ._. Molecular_NNP analysis_NN
        revealed_VBD that_IN BP_NNP 1_CD expression_NN is_VBZ required_VBN for_IN the_DT survival_NN
        of_IN K_NNP 562_CD leukemia_NN cells_NNS ,_, suggesting_VBG that_IN BP_NNP 1_CD might_MD be_VB part_NN
        of_IN an_DT anti-apoptotic_JJ pathway_NN (_( Davenport_NNP GJ_NNP ,_, Fu_NNP S_NNP ,_, Haga_NNP SB_NNP ,_,
        Do_VBP K_NNP ,_, Stevenson_NNP H_NNP ,_, Pinzone_NNP J_NNP ,_, Chase_NNP MB_NNP ,_, Berg_NNP PE_NNP ,_,
        unpublished_JJ data_NNS )_) ._. Furthermore_RB ,_, these_DT results_NNS imply_VBP that_DT
        aberrant_NN BP_NNP 1_CD expression_NN might_MD also_RB be_VB involved_VBN in_IN other_JJ
        malignancies_NNS ._. In_IN the_DT present_JJ study_NN we_PRP analyzed_VBD BP_NNP 1_CD
        expression_NN in_IN human_JJ breast_NN cancer_NN cell_NN lines_NNS and_CC assessed_VBN
        BP_NNP 1_CD expression_NN in_IN invasive_JJ ductal_NN carcinoma_NN tumors_NNS ,_,
        correlating_VBG its_PRP$ expression_NN with_IN age_NN ,_, tumor_NN size_NN ,_, lymph_NN node_NN
        metastasis_NNS ,_, histologic_JJ grade_NN ,_, estrogen_NN receptor_NN (_( ER_NNP )_)
        status_NN ,_, progesterone_NN receptor_NN (_( PR_NNP )_) status_NN ,_, and_CC race_NN ._.
      
      
        Methods_NNP
        
          Cell_NNP lines_NNS
          The_DT breast_NN cancer_NN cell_NN lines_NNS Hs_NNP 578_CD T_NN ,_, MCF_NNP 7_CD ,_, MDA-MB-_NNP 231_CD ,_,
          MDA-MB-_NNP 468_CD ,_, and_CC T-_NNP 47_CD D_NNP were_VBD kindly_RB given_VBN to_TO us_PRP by_IN Dr_NNP
          Angela_NNP Brodie_NNP ;_: MCF_NNP 7_CD ADR_NNP and_CC MDA-MB-_NNP 435_CD S_NNP were_VBD a_DT gift_NN from_IN
          Dr_NNP Joseph_NNP Fontana_NNP ;_: and_CC MCF_NNP 10_CD A_DT was_VBD purchased_VBN from_IN the_DT
          American_NNP Type_NNP Culture_NNP Collection_NNP (_( ATCC_NNP ;_: Manassas_NNP ,_, VA_NNP ,_,
          USA_NNP )_) ._. Cell_NNP lines_NNS were_VBD grown_VBN in_IN Dulbecco_NNP 's_POS modified_VBN
          Eagle_NNP 's_POS medium_NN supplemented_JJ with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN ,_,
          except_IN for_IN MCF_NNP 10_CD A_DT cells_NNS ,_, which_WDT were_VBD grown_VBN as_IN recommended_VBN
          by_IN the_DT ATCC_NNP ._.
        
        
          Human_JJ breast_NN tissues_NNS
          Human_JJ breast_NN tumor_NN samples_NNS were_VBD obtained_VBN from_IN The_DT
          George_NNP Washington_NNP University_NNP Department_NNP of_IN Pathology_NNP and_CC
          the_DT NCI_NNP Cooperative_NNP Human_NNP Tissue_NNP Network_NNP ,_, Southern_NNP
          Division_NNP ,_, all_DT with_IN Institutional_NNP Review_NNP Board_NNP approval_NN ,_,
          and_CC as_RB previously_RB described_VBD [_NN 24_CD ]_NN ._. Breast_NNP tissue_NN
          samples_NNS ,_, 0_CD ._. 5_CD -_: 1_CD ._. 0_CD cm_NN in_IN diameter_NN ,_, were_VBD obtained_VBN from_IN fresh_JJ
          surgical_JJ resection_NN specimens_NNS from_IN patients_NNS with_IN breast_NN
          tumors_NNS ,_, and_CC were_VBD characterized_VBN pathologically_RB in_IN terms_NNS of_IN
          their_PRP$ stage_NN in_IN malignancy_NN ._. The_DT samples_NNS were_VBD snap-frozen_JJ
          in_IN liquid_JJ nitrogen_NN and_CC were_VBD kept_VBN frozen_VBN until_IN use_NN ._. Normal_NNP
          breast_NN tissues_NNS were_VBD obtained_VBN from_IN the_DT periphery_NN of_IN
          specimens_NNS surgically_RB resected_JJ for_IN treatment_NN of_IN cancer_NN or_CC
          from_IN an_DT autopsy_NN specimen_NN obtained_VBN from_IN a_DT patient_NN who_WP had_VBD
          died_VBN of_IN injuries_NNS sustained_VBN in_IN an_DT accident_NN (_( not_RB breast_NN
          cancer_NN )_) ;_: the_DT latter_NN was_VBD obtained_VBN from_IN the_DT Brain_NNP and_CC
          Tissue_NNP Bank_NNP for_IN Developmental_NNP Disorders_NNP at_IN the_DT University_NNP
          of_IN Maryland_NNP ._.
        
        
          RNA_NNP isolation_NN and_CC reverse_VB transcription_NN polymerase_NN
          chain_NN reaction_NN (_( RT-PCR_NNP )_)
          Total_NNP RNA_NNP was_VBD extracted_VBN from_IN human_JJ breast_NN cell_NN lines_NNS ,_,
          frozen_VBN breast_NN tumor_NN tissues_NNS and_CC normal_JJ breast_NN tissues_NNS
          with_IN Trizol_NNP reagent_NN (_( Invitrogen_NNP ,_, Gaithersburg_NNP ,_, MD_NNP ,_, USA_NNP )_)
          in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS protocol_NN ._. Total_NNP RNA_NNP
          (_( 1_CD μg_NN )_) was_VBD used_VBN to_TO synthesize_VB cDNA_NN with_IN a_DT SuperScript_NNP II_NNP
          reverse_VB transcriptase_NN system_NN (_( Invitrogen_NNP )_) ._. After_IN
          synthesis_NN of_IN the_DT first-strand_JJ cDNA_NN ,_, PCR_NNP was_VBD performed_VBN by_IN
          initial_JJ denaturing_VBG at_IN 94_CD °_NN C_NNP for_IN 2_CD min_NN followed_VBN by_IN 28_CD
          cycles_NNS of_IN denaturation_NN at_IN 94_CD °_NN C_NNP for_IN 1_CD min_NN ,_, annealing_VBG at_IN
          60_CD °_NN C_NNP for_IN 1_CD min_NN ,_, and_CC extension_NN at_IN 72_CD °_NN C_NNP for_IN 1_CD ._. 5_CD min_NN ._. The_DT
          PCR_NNP primers_NNS for_IN BP_NNP 1_CD ,_, which_WDT span_VBP an_DT intron_NN ,_, were_VBD
          5_CD '_POS -_: GTATG-GCCACCTCCTGTCTT-_NNP 3_CD '_POS (_( forward_RB )_) and_CC
          5_CD '_POS -_: GAGTA-GATGGTCCTCGGCTT-_NNP 3_CD '_POS (_( reverse_NN )_) ,_, giving_VBG a_DT product_NN
          of_IN 225_CD base_NN pairs_NNS ._. The_DT internal_JJ control_NN for_IN all_DT samples_NNS
          was_VBD β-actin_JJ ._.
        
        
          Statistical_NNP analyses_NNS
          Statistical_NNP analyses_NNS were_VBD used_VBN to_TO determine_VB the_DT
          relationship_NN between_IN BP_NNP 1_CD positivity_NN ,_, measured_VBN by_IN RT-PCR_NNP ,_,
          and_CC clinicopathological_JJ parameters_NNS ._. All_DT 
          P_NN values_NNS were_VBD calculated_VBN with_IN
          Fisher_NNP 's_POS Exact_JJ Test_NNP ._. Tests_NNP were_VBD considered_VBN significant_JJ if_IN
          their_PRP$ associated_VBN 
          P_NN value_NN was_VBD 0_CD ._. 05_CD or_CC less_JJR
          (_( two-tailed_JJ )_) ._. All_DT statistical_JJ analyses_NNS were_VBD performed_VBN
          with_IN SAS_NNP 8_CD ._. 2_CD (_( SAS_NNP Institute_NNP ,_, Cary_NNP ,_, NC_NNP ,_, USA_NNP )_) ._.
        
      
      
        Results_NNS
        
          BP_NNP 1_CD expression_NN in_IN breast_NN cell_NN lines_NNS
          BP_NNP 1_CD mRNA_NN levels_NNS were_VBD analyzed_VBN in_IN a_DT series_NN of_IN breast_NN
          cell_NN lines_NNS by_IN using_VBG RT-PCR_NNP ._. The_DT cell_NN lines_NNS are_VBP derived_VBN
          from_IN breast_NN cancer_NN patients_NNS ,_, with_IN the_DT exception_NN of_IN
          MCF_NNP 10_CD A_DT ,_, which_WDT is_VBZ an_DT immortalized_JJ ,_, non-transformed_JJ
          epithelial_NN cell_NN line_NN [_NN 25_CD ]_NN ._. As_IN shown_VBN in_IN Fig_NNP ._. 1_LS ,_, the_DT
          levels_NNS of_IN BP_NNP 1_CD expression_NN varied_VBD widely_RB between_IN the_DT cell_NN
          lines_NNS ,_, from_IN barely_RB detectable_JJ (_( Hs_NNP 578_CD T_NN ,_, MDA-MB-_NNP 435_CD S_NNP ,_, and_CC
          MCF_NNP 10_CD A_DT ;_: lanes_NNS 2_CD ,_, 6_CD ,_, and_CC 9_CD ,_, respectively_RB )_) to_TO highly_RB
          expressing_VBG (_( MCF_NNP 7_CD ADR_NNP ,_, MDA-MB-_NNP 468_CD ,_, and_CC T-_NNP 47_CD D_NNP ;_: lanes_NNS 4_CD ,_, 7_CD ,_,
          and_CC 8_CD ,_, respectively_RB )_) ;_: MCF_NNP 7_CD and_CC MDA-MB-_NNP 231_CD (_( lanes_NNS 3_CD and_CC 5_CD ,_,
          respectively_RB )_) showed_VBD intermediate_JJ expression_NN ._. For_IN
          comparison_NN ,_, one_CD normal_JJ breast_NN tissue_NN from_IN an_DT autopsy_NN was_VBD
          included_VBN in_IN the_DT first_JJ lane_NN ;_: it_PRP was_VBD BP_NNP 1_CD -_: negative_JJ ._.
          There_EX was_VBD a_DT correlation_NN between_IN BP_NNP 1_CD expression_NN and_CC
          tumorigenesis_NNS in_IN mice_NNS (_( Table_NNP 1_LS )_) ._. The_DT cell_NN lines_NNS that_WDT
          express_VBP little_JJ or_CC no_DT BP_NNP 1_CD (_( Hs_NNP 578_CD T_NN ,_, MDA-MB-_NNP 435_CD S_NNP ,_, and_CC
          MCF_NNP 10_CD A_DT )_) are_VBP not_RB tumorigenic_JJ ,_, whereas_IN MCF_NNP 7_CD ADR_NNP ,_, MDA-MB-_NNP 468_CD ,_,
          and_CC MDA-MB-_NNP 231_CD express_VB BP_NNP 1_CD and_CC are_VBP tumorigenic_JJ ._. MCF_NNP 7_CD and_CC
          T-_NNP 47_CD D_NNP cells_NNS express_VBP variable_JJ BP_NNP 1_CD levels_NNS and_CC are_VBP
          tumorigenic_JJ only_RB in_IN the_DT presence_NN of_IN estradiol_NN [_NN 26_CD 27_CD ]_NN ._.
          BP_NNP 1_CD expression_NN might_MD therefore_RB be_VB involved_VBN in_IN
          tumorigenesis_NNS in_IN mice_NNS ._. Transgenic_NNP studies_NNS would_MD provide_VB
          direct_JJ evidence_NN for_IN this_DT hypothesis_NNS ._.
        
        
          BP_NNP 1_CD expression_NN in_IN breast_NN tumor_NN tissues_NNS
          BP_NNP 1_CD mRNA_NN expression_NN was_VBD examined_VBN in_IN 46_CD invasive_JJ ductal_NN
          breast_NN tumors_NNS including_VBG grades_NNS I_PRP ,_, II_NNP ,_, and_CC III_NNP tumors_NNS and_CC ,_,
          in_IN some_DT cases_NNS ,_, compared_VBN with_IN adjacent_JJ normal_JJ breast_NN
          tissue_NN ._. Of_IN these_DT tumors_NNS ,_, 80_CD %_NN expressed_VBD BP_NNP 1_CD ._. In_IN contrast_NN ,_,
          of_IN seven_CD normal_JJ breast_NN tumors_NNS analyzed_VBD ,_, six_CD were_VBD
          BP_NNP 1_CD -_: negative_JJ and_CC one_CD showed_VBD low_JJ BP_NNP 1_CD expression_NN ._. A_DT
          representative_JJ RT-PCR_NNP analysis_NN of_IN five_CD tumors_NNS ,_, three_CD with_IN
          matched_VBN normal_JJ tissue_NN ,_, is_VBZ shown_VBN in_IN Fig_NNP ._. 2_LS ._. All_DT of_IN the_DT
          tumors_NNS shown_VBN are_VBP ER-negative_NNP and_CC PR-negative_NNP ._. Matched_NNP
          normal_JJ and_CC tumor_NN tissues_NNS from_IN three_CD patients_NNS are_VBP shown_VBN in_IN
          lanes_NNS 1_CD and_CC 2_CD (_( patient_NN 1_LS )_) ,_, 3_CD and_CC 4_CD (_( patient_NN 2_LS )_) ,_, and_CC 5_CD and_CC
          6_CD (_( patient_NN 3_LS )_) ._. No_DT BP_NNP 1_CD expression_NN was_VBD seen_VBN in_IN the_DT normal_JJ
          samples_NNS (_( lanes_NNS 1_CD ,_, 3_CD ,_, and_CC 5_LS )_) ,_, whereas_IN BP_NNP 1_CD was_VBD expressed_VBN in_IN
          all_DT of_IN the_DT tumors_NNS (_( lanes_NNS 2_CD ,_, 4_CD ,_, and_CC 6_CD )_) ._. Two_CD additional_JJ
          tumor_NN tissues_NNS ,_, shown_VBN in_IN lanes_NNS 7_CD and_CC 8_CD ,_, were_VBD positive_JJ for_IN
          BP_NNP 1_CD ;_: matched_VBN samples_NNS were_VBD not_RB available_JJ ._.
          To_TO determine_VB the_DT significance_NN of_IN BP_NNP 1_CD expression_NN in_IN the_DT
          tumor_NN tissues_NNS ,_, clinicopathological_JJ data_NNS were_VBD related_VBN to_TO
          BP_NNP 1_CD expression_NN (_( Table_NNP 2_LS )_) ._. No_DT significant_JJ relationship_NN was_VBD
          detected_VBN between_IN BP_NNP 1_CD status_NN and_CC age_NN ,_, tumor_NN size_NN ,_, or_CC lymph_NN
          node_NN metastasis_NNS ._. Because_IN 5_CD -_: year_NN survival_NN data_NNS were_VBD not_RB
          available_JJ for_IN some_DT patients_NNS ,_, we_PRP were_VBD not_RB able_JJ to_TO evaluate_VB
          survival_NN outcome_NN ._. BP_NNP 1_CD expression_NN was_VBD significantly_RB more_RBR
          prevalent_JJ in_IN ER-negative_NNP tumors_NNS ,_, of_IN which_WDT 100_CD %_NN were_VBD
          BP_NNP 1_CD -_: positive_JJ ,_, compared_VBN with_IN ER-positive_NNP tumors_NNS ,_, of_IN which_WDT
          73_CD %_NN were_VBD BP_NNP 1_CD -_: positive_JJ (_( 
          P_NN =_SYM 0_CD ._. 03_CD )_) ._. There_EX was_VBD also_RB a_DT
          significant_JJ difference_NN in_IN BP_NNP 1_CD expression_NN between_IN
          PR-negative_NNP tumors_NNS ,_, of_IN which_WDT 96_CD %_NN were_VBD BP_NNP 1_CD -_: positive_JJ ,_, and_CC
          PR-positive_NNP tumors_NNS ,_, of_IN which_WDT 67_CD %_NN were_VBD BP_NNP 1_CD -_: positive_JJ (_( 
          P_NN =_SYM 0_CD ._. 02_CD )_) ._. BP_NNP 1_CD expression_NN was_VBD
          associated_VBN with_IN race_NN :_: it_PRP was_VBD expressed_VBN in_IN 89_CD %_NN of_IN the_DT
          tumors_NNS of_IN African_NNP American_JJ women_NNS but_CC in_IN only_RB 57_CD %_NN of_IN the_DT
          tumors_NNS of_IN Caucasian_NNP women_NNS (_( 
          P_NN =_SYM 0_CD ._. 04_CD )_) ._. There_EX was_VBD no_DT significant_JJ
          difference_NN in_IN BP_NNP 1_CD expression_NN between_IN the_DT three_CD tumor_NN
          grades_NNS :_: BP_NNP 1_CD was_VBD expressed_VBN in_IN 80_CD %_NN of_IN grade_NN I_PRP tumors_NNS ,_, 73_CD %_NN
          of_IN grade_NN II_NNP tumors_NNS and_CC 90_CD %_NN of_IN grade_NN III_NNP tumors_NNS ._.
        
      
      
        Discussion_NNP
        In_IN the_DT present_JJ study_NN we_PRP found_VBD that_IN 80_CD %_NN of_IN invasive_JJ
        ductal_NN breast_NN tumors_NNS expressed_VBD BP_NNP 1_CD ,_, a_DT member_NN of_IN the_DT DLX_NNP
        homeobox_NN gene_NN family_NN ._. In_IN contrast_NN ,_, only_RB 14_CD %_NN of_IN normal_JJ
        breast_NN tissues_NNS expressed_VBD BP_NNP 1_CD ._. Our_PRP$ previous_JJ studies_NNS showed_VBD
        that_IN BP_NNP 1_CD is_VBZ also_RB expressed_VBN in_IN leukemia_NN and_CC has_VBZ
        characteristics_NNS of_IN an_DT oncogene_NN :_: in_IN acute_JJ myeloid_NN leukemia_NN ,_,
        BP_NNP 1_CD is_VBZ highly_RB expressed_VBN in_IN the_DT bone_NN marrow_NN of_IN 63_CD %_NN of_IN
        patients_NNS overall_JJ ,_, with_IN a_DT preponderance_NN of_IN expression_NN in_IN
        pediatric_JJ patients_NNS [_NN 11_CD ]_NN ._. When_WRB overexpressed_JJ in_IN a_DT
        leukemia_NN cell_NN line_NN (_( K_NNP 562_CD )_) ,_, BP_NNP 1_CD increased_VBD the_DT ability_NN of_IN
        cells_NNS to_TO grow_VB in_IN soft_JJ agar_NN ,_, an_DT indicator_NN of_IN leukemogenic_JJ
        potential_NN ,_, up_IN to_TO 45_CD -_: fold_VB [_NN 11_CD ]_NN ._. Consistent_NNP with_IN a_DT
        possible_JJ oncogenic_JJ role_NN for_IN BP_NNP 1_CD in_IN breast_NN cancer_NN was_VBD the_DT
        observation_NN that_IN its_PRP$ expression_NN was_VBD correlated_JJ with_IN the_DT
        ability_NN of_IN breast_NN cancer_NN cell_NN lines_NNS to_TO cause_VB mammary_JJ tumors_NNS
        in_IN mice_NNS ._.
        Recent_JJ studies_NNS have_VBP shown_VBN that_DT abrogation_NN of_IN BP_NNP 1_CD
        expression_NN in_IN a_DT leukemia_NN cell_NN line_NN leads_VBZ to_TO apoptosis_NNS
        (_( Davenport_NNP GJ_NNP ,_, Fu_NNP S_NNP ,_, Haga_NNP SB_NNP ,_, Do_VBP K_NNP ,_, Stevenson_NNP H_NNP ,_, Pinzone_NNP J_NNP ,_,
        Chase_NNP MB_NNP ,_, Berg_NNP PE_NNP ,_, unpublished_JJ data_NNS )_) ._. Coupled_VBN with_IN the_DT
        increased_VBN clonogenicity_NN resulting_VBG from_IN overexpression_NN of_IN
        BP_NNP 1_CD ,_, these_DT observations_NNS suggest_VBP that_IN the_DT expression_NN of_IN BP_NNP 1_CD
        in_IN breast_NN tissue_NN might_MD also_RB lead_VB to_TO increased_VB survival_NN and_CC ,_,
        conversely_RB ,_, that_IN the_DT abrogation_NN of_IN BP_NNP 1_CD expression_NN in_IN
        malignant_JJ breast_NN tissue_NN could_MD cause_VB apoptosis_NNS of_IN those_DT
        cells_NNS expressing_VBG BP_NNP 1_CD ._.
        Estrogen_NNP and_CC progesterone_NN ,_, which_WDT stimulate_VB the_DT growth_NN of_IN
        breast_NN epithelium_NN ,_, are_VBP two_CD crucial_JJ hormones_NNS involved_VBN not_RB
        only_RB in_IN normal_JJ breast_NN development_NN but_CC also_RB in_IN
        carcinogenesis_NNS of_IN breast_NN epithelium_NN and_CC progression_NN of_IN
        breast_NN cancer_NN [_NN 28_CD ]_NN ._. About_IN 40_CD %_NN of_IN breast_NN cancers_NNS are_VBP
        ER-negative_NNP [_NN 28_CD ]_NN ._. ER-negative_NNP tumors_NNS are_VBP unresponsive_JJ to_TO
        anti-estrogen_JJ therapy_NN ,_, probably_RB because_IN of_IN constitutive_JJ
        growth_NN factor_NN expression_NN [_NN 28_CD 29_CD ]_NN ._. In_IN general_JJ ,_, these_DT
        tumors_NNS have_VBP a_DT higher_JJR histologic_JJ grade_NN and_CC a_DT higher_JJR
        proliferative_JJ rate_NN and_CC are_VBP associated_VBN with_IN poorer_JJR prognosis_NN
        [_NN 28_CD ]_NN ._. The_DT finding_VBG that_IN 100_CD %_NN of_IN ER-negative_NNP tumors_NNS
        expressed_VBD BP_NNP 1_CD might_MD therefore_RB be_VB highly_RB relevant_JJ to_TO both_DT
        the_DT prognosis_NN and_CC therapy_NN of_IN those_DT difficult-to-treat_JJ
        tumors_NNS ._.
        It_PRP is_VBZ well_RB known_VBN that_IN African_NNP American_JJ women_NNS have_VBP a_DT
        higher_JJR mortality_NN rate_NN from_IN breast_NN cancer_NN than_IN Caucasian_NNP
        women_NNS (_( reviewed_VBN by_IN Mancino_NNP and_CC colleagues_NNS [_NN 30_CD ]_NN )_) ._.
        Although_IN socioeconomic_JJ factors_NNS account_VBP for_IN some_DT of_IN this_DT
        difference_NN ,_, several_JJ recent_JJ studies_NNS have_VBP shown_VBN that_IN the_DT
        median_JJ survival_NN of_IN African_NNP American_JJ women_NNS presenting_VBG with_IN
        Stage_NNP III_NNP or_CC IV_NNP disease_NN was_VBD significantly_RB lower_JJR than_IN that_DT
        of_IN Caucasian_NNP women_NNS diagnosed_VBN at_IN the_DT same_JJ stage_NN of_IN disease_NN :_:
        in_IN Stage_NNP III_NNP disease_NN the_DT median_JJ survival_NN was_VBD 91_CD ._. 3_LS months_NNS
        for_IN Caucasian_NNP patients_NNS and_CC only_RB 36_CD ._. 0_CD months_NNS for_IN African_NNP
        American_JJ patients_NNS ,_, whereas_IN in_IN Stage_NNP IV_NNP disease_NN the_DT median_JJ
        survival_NN was_VBD reduced_VBN to_TO 24_CD ._. 0_CD months_NNS for_IN Caucasian_NNP patients_NNS
        and_CC 8_CD ._. 9_CD months_NNS for_IN African_NNP American_JJ patients_NNS [_NN 30_CD 31_CD ]_NN ._.
        African_NNP American_JJ women_NNS also_RB have_VBP a_DT higher_JJR risk_NN of_IN
        ER-negative_NNP tumors_NNS after_IN adjustment_NN is_VBZ made_VBN for_IN stage_NN and_CC
        age_NN at_IN diagnosis_NN ._. These_DT results_NNS have_VBP led_VBN to_TO speculation_NN
        that_IN there_EX could_MD be_VB biological_JJ differences_NNS between_IN African_NNP
        American_NNP and_CC Caucasian_NNP women_NNS that_WDT contribute_VBP to_TO the_DT
        differences_NNS in_IN outcome_NN ._. Interestingly_RB ,_, more_RBR African_NNP
        American_JJ women_NNS than_IN Caucasian_NNP women_NNS were_VBD BP_NNP 1_CD -_: positive_JJ (_( 
        P_NN =_SYM 0_CD ._. 04_CD )_) ._. It_PRP will_MD be_VB important_JJ to_TO
        expand_VB further_VB the_DT number_NN of_IN women_NNS studied_VBN to_TO determine_VB
        whether_IN BP_NNP 1_CD expression_NN might_MD be_VB one_CD biological_JJ factor_NN that_IN
        underlies_NNS survival_NN differences_NNS between_IN African_NNP American_NNP and_CC
        Caucasian_NNP women_NNS ._.
        Because_IN BP_NNP 1_CD was_VBD expressed_VBN in_IN all_DT tumor_NN grades_NNS ,_, we_PRP
        propose_VBP that_IN it_PRP is_VBZ activated_VBN in_IN an_DT early_JJ stage_NN of_IN malignant_JJ
        development_NN or_CC even_RB in_IN a_DT premalignant_NN state_NN ._. We_PRP have_VBP
        therefore_RB begun_VBN to_TO examine_VB ductal_NN carcinoma_NN 
        in_IN situ_NN (_( DCIS_NNP )_) ,_, which_WDT are_VBP preinvasive_JJ
        malignant_JJ lesions_NNS derived_VBN from_IN epithelial_NN cells_NNS ,_, and_CC
        fibroadenomas_NNS ,_, which_WDT are_VBP non-malignant_JJ tumors_NNS composed_VBN of_IN
        epithelial_NN and_CC stromal_NN cells_NNS [_NN 32_CD 33_CD ]_NN ._. So_RB far_RB we_PRP have_VBP
        analyzed_VBN one_CD DCIS_NNP ,_, which_WDT was_VBD BP_NNP 1_CD -_: positive_JJ ,_, and_CC two_CD
        fibroadenomas_NNS ,_, both_DT of_IN which_WDT were_VBD BP_NNP 1_CD -_: positive_JJ ,_, compared_VBN
        with_IN no_DT expression_NN in_IN the_DT matched_VBN normal_JJ tissue_NN for_IN each_DT
        fibroadenoma_NN (_( data_NNS not_RB shown_VBN )_) ._. The_DT sample_NN number_NN is_VBZ very_RB
        small_JJ ,_, but_CC the_DT fact_NN that_IN any_DT of_IN the_DT DCISs_NNP or_CC fibroadenoma_NN
        tumors_NNS are_VBP positive_JJ for_IN BP_NNP 1_CD demonstrates_VBZ that_DT activation_NN of_IN
        BP_NNP 1_CD might_MD be_VB an_DT early_JJ event_NN ,_, perhaps_RB promoting_VBG cell_NN
        survival_NN as_IN seems_VBZ to_TO occur_VB in_IN leukemia_NN cells_NNS ._. This_DT idea_NN is_VBZ
        also_RB supported_VBN by_IN the_DT fact_NN that_IN BP_NNP 1_CD is_VBZ as_IN likely_JJ to_TO be_VB
        expressed_VBN in_IN small_JJ tumors_NNS (_( less_JJR than_IN 2_CD ._. 0_CD cm_NN )_) as_IN it_PRP is_VBZ in_IN
        larger_JJR tumors_NNS (_( 2_CD ._. 0_CD cm_NN or_CC more_JJR )_) ._.
        The_DT mechanism_NN for_IN overexpression_NN of_IN BP_NNP 1_CD in_IN breast_NN cancer_NN
        is_VBZ unknown_JJ ._. However_RB ,_, because_IN of_IN its_PRP$ map_NN location_NN at_IN
        17_CD q_NN 21_CD -_: 22_CD [_NN 23_CD ]_NN ,_, the_DT BP_NNP 1_CD gene_NN is_VBZ a_DT potential_JJ candidate_NN for_IN
        DNA_NNP amplification_NN ,_, which_WDT could_MD lead_VB to_TO its_PRP$ activation_NN or_CC
        overexpression_NN ._. This_DT hypothesis_NNS is_VBZ based_VBN on_IN the_DT fact_NN that_IN
        two_CD regions_NNS on_IN chromosome_NN 17_CD q_NN are_VBP sometimes_RB amplified_VBN in_IN
        breast_NN cancer_NN ,_, one_CD at_IN 17_CD q_NN 11_CD -_: 21_CD and_CC another_DT at_IN 17_CD q_NN 22_CD -_: 24_CD [_NN 34_CD
        35_CD ]_NN ._. The_DT locus_JJ of_IN BP_NNP 1_CD is_VBZ also_RB near_IN BRCA_NNP 1_CD ;_: the_DT
        implications_NNS of_IN this_DT proximity_NN are_VBP not_RB yet_RB known_VBN ._.
        To_TO begin_VB to_TO identify_VB genes_NNS that_WDT might_MD be_VB targets_NNS of_IN BP_NNP 1_CD ,_,
        we_PRP have_VBP overexpressed_JJ BP_NNP 1_CD in_IN K_NNP 562_CD cells_NNS and_CC screened_VBD a_DT
        microarray_NN (_( Davenport_NNP GJ_NNP ,_, Fu_NNP S_NNP ,_, Haga_NNP SB_NNP ,_, Do_VBP K_NNP ,_, Stevenson_NNP H_NNP ,_,
        Pinzone_NNP J_NNP ,_, Chase_NNP MB_NNP ,_, Berg_NNP PE_NNP ,_, unpublished_JJ data_NNS )_) ._. Although_IN
        K_NNP 562_CD cells_NNS are_VBP derived_VBN from_IN leukemia_NN ,_, among_IN the_DT genes_NNS
        showing_VBG altered_VBN regulation_NN were_VBD several_JJ that_WDT are_VBP also_RB
        dysregulated_JJ in_IN breast_NN cancer_NN ,_, including_VBG c-_NN 
        myc_NN and_CC cyclin_NN D_NNP 2_CD ;_: their_PRP$ altered_VBN
        expression_NN was_VBD verified_VBN by_IN real-time_JJ PCR_NNP ._. c-_NN 
        myc_NN was_VBD upregulated_JJ in_IN K_NNP 562_CD cells_NNS
        overexpressing_VBG BP_NNP 1_CD ,_, and_CC c-_NN Myc_NNP protein_NN is_VBZ highly_RB expressed_VBN
        in_IN more_JJR than_IN half_NN of_IN breast_NN cancer_NN patients_NNS [_NN 36_CD ]_NN ._. Cyclin_NNP
        D_NNP 2_CD ,_, downregulated_JJ on_IN the_DT array_NN ,_, is_VBZ repressed_VBN in_IN breast_NN
        cancer_NN [_NN 37_CD ]_NN ._. It_PRP will_MD be_VB important_JJ to_TO determine_VB whether_IN
        either_DT of_IN those_DT genes_NNS is_VBZ a_DT target_NN for_IN BP_NNP 1_CD in_IN breast_NN
        cancer_NN ._.
        These_DT data_NNS strongly_RB implicate_VB BP_NNP 1_CD in_IN breast_NN cancer_NN ._. More_JJR
        case_NN studies_NNS are_VBP underway_NN to_TO further_VB strengthen_VB our_PRP$
        findings_NNS and_CC to_TO determine_VB whether_IN there_EX is_VBZ a_DT statistical_JJ
        association_NN between_IN BP_NNP 1_CD expression_NN and_CC prognosis_NN or_CC outcome_NN
        of_IN breast_NN cancer_NN patients_NNS ._.
      
      
        Conclusion_NNP
        These_DT data_NNS demonstrate_VBP a_DT statistically_RB significant_JJ
        association_NN between_IN the_DT expression_NN of_IN the_DT transcription_NN
        factor_NN BP_NNP 1_CD ,_, not_RB previously_RB implicated_VBN in_IN breast_NN cancer_NN ,_, and_CC
        ER-negative_NNP breast_NN tumors_NNS ._. This_DT ,_, together_RB with_IN other_JJ
        studies_NNS ,_, strongly_RB suggests_VBZ that_IN BP_NNP 1_CD has_VBZ oncogenic_JJ
        properties_NNS ,_, making_VBG it_PRP a_DT new_JJ potential_JJ target_NN in_IN breast_NN
        tumors_NNS ,_, especially_RB the_DT difficult-to-treat_JJ ER-negative_NNP
        tumors_NNS ._. Interestingly_RB ,_, BP_NNP 1_CD is_VBZ expressed_VBN in_IN 73_CD -_: 90_CD %_NN of_IN
        tumors_NNS ,_, including_VBG all_DT grades_NNS ._. This_DT finding_VBG and_CC the_DT
        observation_NN that_IN fibroadenomas_NNS (_( non-malignant_JJ tumors_NNS )_) can_MD
        express_VB BP_NNP 1_CD strongly_RB suggest_VBP that_IN its_PRP$ activation_NN might_MD be_VB
        associated_VBN with_IN loss_NN of_IN growth_NN regulation_NN ,_, which_WDT is_VBZ
        consistent_JJ with_IN our_PRP$ molecular_JJ data_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        DCIS_NNP =_SYM ductal_NN carcinoma_NN 
        in_IN situ_NN ;_: ER_NNP =_SYM estrogen_NN receptor_NN ;_: HB_NNP
        =_SYM homeobox_NN ;_: HD_NNP =_SYM homeodomain_NN ;_: PR_NNP =_SYM progesterone_NN receptor_NN ;_:
        RT-PCR_NNP =_SYM reverse_VB transcription_NN polymerase_NN chain_NN
        reaction_NN ._.
      
    
  
